A biological characterization of patients with postmenopausal Parkinson's disease.
CSF biomarkers
Gender
Hormones
Menopause
Parkinson’s disease
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
16 Mar 2024
16 Mar 2024
Historique:
received:
23
01
2024
accepted:
14
02
2024
revised:
13
02
2024
medline:
16
3
2024
pubmed:
16
3
2024
entrez:
16
3
2024
Statut:
aheadofprint
Résumé
Menopause increases the risk for Parkinson's disease (PD), although the underlying biological mechanisms have not been established in patients. Here, we aimed to understand the basis of menopause-related vulnerability to PD. Main motor and non-motor scores, blood levels of estradiol, testosterone, follicle-stimulating hormone, and luteinizing hormone, CSF levels of total α-synuclein, amyloid-β-42, amyloid-β-40, total tau, and phosphorylated-181-tau were examined in 45 women with postmenopausal-onset PD and 40 age-matched controls. PD patients had higher testosterone and lower estradiol levels than controls, and the residual estradiol production was associated with milder motor disturbances and lower dopaminergic requirements. In PD but not in controls, follicle-stimulating hormone levels correlated with worse cognitive scores and CSF markers of amyloidopathy and neuronal loss. In conclusion, menopause-related hormonal changes might differentially contribute to clinical-pathological trajectories of PD, accounting for the peculiar vulnerability to the disease.
Identifiants
pubmed: 38492015
doi: 10.1007/s00415-024-12258-8
pii: 10.1007/s00415-024-12258-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : Project MNESYS (PE0000006) - A Multiscale integrated approach to the study of the nervous system in health
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : disease (DN. 1553 11.10.2022)
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Picillo M, Lafontant DE, Bressman S et al (2022) Sex-related longitudinal change of motor, non-motor, and biological features in early Parkinson’s disease. J Parkinsons Dis. https://doi.org/10.3233/JPD-212892
doi: 10.3233/JPD-212892
pubmed: 34744052
pmcid: 8842783
Jurado-Coronel JC, Cabezas R, Ávila Rodríguez MF et al (2018) Sex differences in Parkinson’s disease: features on clinical symptoms, treatment outcome, sexual hormones and genetics. Front Neuroendocrinol 50:18–30. https://doi.org/10.1016/j.yfrne.2017.09.002
doi: 10.1016/j.yfrne.2017.09.002
pubmed: 28974386
Hall JE (2015) Endocrinology of the menopause. Endocrinol Metab Clin North Am 44(3):485–496. https://doi.org/10.1016/j.ecl.2015.05.010
doi: 10.1016/j.ecl.2015.05.010
pubmed: 26316238
pmcid: 6983294
Bovenzi R, Schirinzi T, Pierantozzi M et al (2020) Clinical course of paroxysmal dyskinesias throughout pregnancy. Parkinsonism Relat Disord 80:19–20. https://doi.org/10.1016/j.parkreldis.2020.09.017
doi: 10.1016/j.parkreldis.2020.09.017
pubmed: 32932023
Bovenzi R, Conti M, Degoli GR et al (2023) Shaping the course of early-onset Parkinson’s disease: insights from a longitudinal cohort. Neurol Sci. https://doi.org/10.1007/s10072-023-06826-5
doi: 10.1007/s10072-023-06826-5
pubmed: 37684511
pmcid: 10791711
Bovenzi R, Conti M, Schirinzi T (2023) Pharmacotherapy for Sydenham’s chorea: where are we and where do we need to be? Expert Opin Pharmacother. https://doi.org/10.1080/14656566.2023.2216380
doi: 10.1080/14656566.2023.2216380
pubmed: 37204415
Bovenzi R, Conti M, Degoli GR et al (2023) Pregnancy, fertile life factors, and associated clinical course in PRKN early-onset Parkinson’s disease. Neurol Sci. https://doi.org/10.1007/s10072-023-07029-8
doi: 10.1007/s10072-023-07029-8
pubmed: 37684511
pmcid: 10791711
Bovenzi R, Sancesario GM, Conti M et al (2023) Sex hormones differentially contribute to Parkinson’s disease in males: a multimodal biomarker study. Eur J Neurol. https://doi.org/10.1111/ene.15801
doi: 10.1111/ene.15801
pubmed: 38130035
Schirinzi T, Di Lazzaro G, Sancesario GM et al (2020) Young-onset and late-onset Parkinson’s disease exhibit a different profile of fluid biomarkers and clinical features. Neurobiol Aging. https://doi.org/10.1016/j.neurobiolaging.2020.02.012
doi: 10.1016/j.neurobiolaging.2020.02.012
pubmed: 32169356
Schirinzi T, Zenuni H, Grillo P et al (2022) Tau and amyloid-β peptides in serum of patients with Parkinson’s disease: correlations with CSF levels and clinical parameters. Front Neurol. https://doi.org/10.3389/fneur.2022.748599
doi: 10.3389/fneur.2022.748599
pubmed: 35370899
pmcid: 8964594
Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601. https://doi.org/10.1002/mds.26424
doi: 10.1002/mds.26424
pubmed: 26474316
Goetz CG, Tilley BC, Shaftman SR, et al (2008) Movement disorder society-sponsored revision of the unified parkinson’s disease rating scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord. https://doi.org/10.1002/mds.22340
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. https://doi.org/10.1016/0022-3956(75)90026-6
doi: 10.1016/0022-3956(75)90026-6
pubmed: 1202204
Chaudhuri KR, Martinez-Martin P, Brown RG et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Results from an international pilot study. Mov Disord. https://doi.org/10.1002/mds.21596
doi: 10.1002/mds.21596
pubmed: 18081162
Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide. Mov Disord Clin Pract 7(3):343–345. https://doi.org/10.1002/mdc3.12921
doi: 10.1002/mdc3.12921
pubmed: 32258239
pmcid: 7111582
Cilia R, Cereda E, Piatti M et al (2023) Levodopa equivalent dose of safinamide: a multicenter longitudinal, case-control study. Mov Disord Clin Pract. https://doi.org/10.1002/mdc3.13681
doi: 10.1002/mdc3.13681
pubmed: 38291839
pmcid: 10828621
Cereda E, Barichella M, Cassani E et al (2013) Reproductive factors and clinical features of Parkinson’s disease. Parkinsonism Relat Disord. https://doi.org/10.1016/j.parkreldis.2013.07.020
doi: 10.1016/j.parkreldis.2013.07.020
pubmed: 23931933
Sleumer B, Zwerwer J, van Faassen M et al (2023) An antibody-free LC-MS/MS method for the quantification of sex hormone binding globulin in human serum and plasma. Clin Chem Lab Med (CCLM). https://doi.org/10.1515/cclm-2022-1225
doi: 10.1515/cclm-2022-1225
pubmed: 36773321
Schirinzi T, Sancesario GM, Di Lazzaro G et al (2018) Clinical value of CSF amyloid-beta-42 and tau proteins in progressive supranuclear palsy. J Neural Transm. https://doi.org/10.1007/s00702-018-1893-1
doi: 10.1007/s00702-018-1893-1
pubmed: 29948175
Cerri S, Mus L, Blandini F (2019) Parkinson’s disease in women and men: what’s the difference? J Parkinsons Dis 9(3):501–515. https://doi.org/10.3233/JPD-191683
doi: 10.3233/JPD-191683
pubmed: 31282427
pmcid: 6700650
Barakat R, Oakley O, Kim H et al (2016) Extra-gonadal sites of estrogen biosynthesis and function. BMB Rep 49(9):488–496. https://doi.org/10.5483/bmbrep.2016.49.9.141
doi: 10.5483/bmbrep.2016.49.9.141
pubmed: 27530684
pmcid: 5227141
Kompoliti K (2003) Estrogen and Parkinson’s disease. Front Biosci 8(6):s391–s400. https://doi.org/10.2741/1070
doi: 10.2741/1070
pubmed: 12700049
Picillo M, Nicoletti A, Fetoni V et al (2017) The relevance of gender in Parkinson’s disease: a review. J Neurol 264(8):1583–1607. https://doi.org/10.1007/s00415-016-8384-9
doi: 10.1007/s00415-016-8384-9
pubmed: 28054129
Baker JM, Hung AY (2017) Movement disorders in women. Semin Neurol. https://doi.org/10.1055/s-0037-1608845
doi: 10.1055/s-0037-1608845
pubmed: 29270938
Hruska RE, Silbergeld EK (1980) Estrogen treatment enhances dopamine receptor sensitivity in the rat striatum. Eur J Pharmacol. https://doi.org/10.1016/0014-2999(80)90081-3
doi: 10.1016/0014-2999(80)90081-3
pubmed: 7408951
Parazzini F (2007) Determinants of age at menopause in women attending menopause clinics in Italy. Maturitas. https://doi.org/10.1016/j.maturitas.2006.09.003
doi: 10.1016/j.maturitas.2006.09.003
pubmed: 17069999
Ragonese P, D’Amelio M, Salemi G et al (2004) Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology. https://doi.org/10.1212/WNL.62.11.2010
doi: 10.1212/WNL.62.11.2010
pubmed: 15184606
Giancarlo P, Fanny A, Emmanuel R et al (2022) Reproductive characteristics, use of exogenous hormones and Parkinson disease in women from the E3N study. Brain. https://doi.org/10.1093/brain/awac440
doi: 10.1093/brain/awac440
Lee YH, Cha J, Chung SJ et al (2019) Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson’s disease. Sci Rep. https://doi.org/10.1038/s41598-019-47026-6
doi: 10.1038/s41598-019-47026-6
pubmed: 31892717
pmcid: 6938501
Xiong J, Kang SS, Wang Z et al (2022) FSH blockade improves cognition in mice with Alzheimer’s disease. Nature. https://doi.org/10.1038/s41586-022-04463-0
doi: 10.1038/s41586-022-04463-0
pubmed: 36477529
pmcid: 9940301
Casadesus G, Webber KM, Atwood CS et al (2006) Luteinizing hormone modulates cognition and amyloid-β deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta Mol Basis Dis. https://doi.org/10.1016/j.bbadis.2006.01.008
doi: 10.1016/j.bbadis.2006.01.008
Barron AM, Fuller SJ, Verdile G, Martins RN (2006) Reproductive hormones modulate oxidative stress in Alzheimer’s disease. Antioxid Redox Signal 8(11–12):2047–2059. https://doi.org/10.1089/ars.2006.8.2047
doi: 10.1089/ars.2006.8.2047.
pubmed: 17034349
Bowen RL, Verdile G, Liu T et al (2004) Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-β precursor protein and amyloid-β deposition. J Biol Chem. https://doi.org/10.1074/jbc.M311993200
doi: 10.1074/jbc.M311993200
pubmed: 15492007
Verdile G, Laws SM, Henley D et al (2014) Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer’s disease. Mol Psychiatry. https://doi.org/10.1038/mp.2012.147
doi: 10.1038/mp.2012.147
pubmed: 23089633
Lemprière S (2022) FSH provides link between menopause and AD. Nat Rev Neurol. https://doi.org/10.1038/s41582-022-00647-4
doi: 10.1038/s41582-022-00647-4
pubmed: 36319693
pmcid: 9244876
Short RA, O’brien PC, Graff-Radford NR (2001) Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc. https://doi.org/10.4065/76.9.906
doi: 10.4065/76.9.906
pubmed: 11560301
Majbour NK, Abdi IY, Dakna M et al (2021) Cerebrospinal α-synuclein oligomers reflect disease motor severity in DeNoPa longitudinal cohort. Mov Disord. https://doi.org/10.1002/mds.28611
doi: 10.1002/mds.28611
pubmed: 33978256
Schwenkhagen A (2007) Hormonal changes in menopause and implications on sexual health. J Sex Med. https://doi.org/10.1111/j.1743-6109.2007.00448.x
doi: 10.1111/j.1743-6109.2007.00448.x
pubmed: 17394594
Okun MS, Walter BL, McDonald WM et al (2002) Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease. Arch Neurol. https://doi.org/10.1001/archneur.59.11.1750
doi: 10.1001/archneur.59.11.1750
pubmed: 12433262
Bourque M, Soulet D, Di Paolo T (2021) Androgens and Parkinson’s disease: a review of human studies and animal models. Androg Clin Res Ther. https://doi.org/10.1089/andro.2021.0011
doi: 10.1089/andro.2021.0011
pubmed: 35024696
pmcid: 8744006
Ben-Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22(6):724–763. https://doi.org/10.1210/edrv.22.6.0451
doi: 10.1210/edrv.22.6.0451
pubmed: 11739329
Yuk J-S, Jeong SH (2023) Association between menopausal hormone therapy and risk for Parkinson’s disease. J Parkinsons Dis 13:1357–1367. https://doi.org/10.3233/JPD-230230
doi: 10.3233/JPD-230230
pubmed: 37980684
pmcid: 10741322